|Bid||40.08 x 4000|
|Ask||40.27 x 900|
|Day's Range||40.13 - 40.44|
|52 Week Range||36.41 - 42.32|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||40.45|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||1.98 (4.88%)|
|1y Target Est||44.33|
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
[Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market has made a huge improvement in the first half of 2019 from where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now,disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the backburner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally.Why is that?Markets that are pricing in the negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 6 Stocks Ready to Bounce on a Trade Deal With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors expected more from Sony's (NYSE:SNE) earnings report when the company posted results on Feb. 1. Revenue of 2.4 trillion yen in the third-quarter missed estimates for 2.67 trillion yen.Adding salt to the wound, many SNE investors are fretting over Sony's weaker sales outlook, with smartphone and camera sales lagging. On the flipside, the PlayStation 4 business still could rebound. Even though the console cycle is many years old, customers will continue to buy new game titles. And in the smartphone space, a refresh in the second half of this year may give customers a reason to buy a new Sony device again.Trading more than 10$ below its 52-week high, Sony stock clearly deserves its spot among the best undervalued stocks to buy now. Celestica (CLS)Celestica (NYSE:CLS) reported fourth-quarter revenue of $1.73 billion, up 10% from last year. Net earnings rose $46.5 million to $60.1 million, bringing in earnings of 44 cents a share. However, investors were unimpressed with the weak sequential revenue in its Communications, ATS and CCS segments, which were either flat or down. Still, revenue from all segments grew in the double digits from last year.Celestica ended the year with $422 million in cash and cash equivalents. Net cash fell $335 million for the year. And the balance sheet is not as strong as it could be, with non-IFRS debt leverage at 2.6X.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is an undervalued play worth considering. Allergan (AGN)Generic drug supplier Allergan (NYSE:AGN) fell over 10% in late January and early February for two reasons. First, its fourth-quarter earnings report did not please investors. Operating income sank 11.8% year-over-year, and revenue fell 5.8% YoY to $4.08 billion.On Feb. 1, the Food and Drug Administration approved Evolus' (NASDAQ:EOLS) Jeuveau. This product competes directly with Allergan's Botox. Pricing could come in at 20% below that of Botox, putting pressure on Allergan's bottom line.Be warned: it's likely that AGN stock will continue to sell off as investors price in the worst case scenario for Botox. Even though management already expects some pricing erosion, it is confident that the sales volume will taper off slowly. But this is good news for investors in search of a bargain, as the more the stock falls, the more discount value investors get on AGN stock.As Allergan launches new products this year, it will offset the negative impact of generic drug competition for Botox, making it an undervalued stock to watch. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January appears greatly overdone. The market all but erased the powerful uptrend in the stock that began after INVA sold off in November 2018 and bottomed at $14.The FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo; $51.7 million came from global net sales of Revar/Breo Ellipta.On Feb. 6, Innoviva reported revenue of $79.86 million, up 14.9% from last year. With the stock trading at a forward price-to-earnings ratio of 9.3, the price-earnings-to-growth ratio is 0.45. As such, this general pessimism has created an appealing entry point to INVA stock. * 6 Stocks Ready to Bounce on a Trade Deal Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now. Vodafone (VOD)Telecom stocks are out of favor.. But Vodafone (NASDAQ: VOD) is down the most among the major names in the sector, falling over 35% from its 52-week high.Third-quarter results for VOD, which ended on Dec. 31, missed analysts' consensus sales forecasts. Vodafone continued to under-perform in Europe, due to rising competition. Although the company highlighted improving customer trends in Italy, Germany, and reduced churn in Spain, this was not enough to prevent revenue falling 5.6% in Europe and 6.8% overall.With all that bad news, it is little wonder why the stock has been marching lower. But VOD still has ways to mend the wound. The company could trim the dividend and re-allocate its resources toward advertising and capital expenditures. That would put it in a better position to compete with its European counterparts. And the stock would respond if those efforts lead to better revenue numbers.Vodafone shares pay a dividend yield of nearly 6%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal Compare Brokers The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters. The drugmaker has bundled the non-core drugs into three different portfolios and has hired boutique investment bank Greenhill to market the products to separate bidders, said three sources familiar with the matter, speaking on condition of anonymity. Information packages for two portfolios consisting of Latin American drugs and Physiogel skin care products were sent out to prospective bidders earlier this week, the sources said.
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters. Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure.
Looking deeper into a target of a CRISPR deal, a fundraising for more-targeted approach to mental health therapies and more in our Health Care Digest.
(Bloomberg Opinion) -- Pfizer Inc. is demonstrating once again how expensive it is for pharma firms to buy their way to growth.The company announced Monday morning that it’s paying almost $11 billion for cancer drugmaker Array Biopharma Inc. The deal would bolster Pfizer’s cancer portfolio and add medicines that could meaningfully augment sales and profit. But the company isn’t getting much of a bargain, and its recent track record with a similar deal is a cautionary tale for investors. Pfizer’s relatively anemic projected sales growth and drug pipeline mean that, cost aside, a deal like this makes sense. Cancer is a particularly attractive market for drugmakers, offering both limited pricing pressure and an expanding set of potential treatments and areas to target; Array’s lead medicines Braftovi and Mektovi are already approved for melanoma patients and recently produced promising data in colon cancer. Also, the company has developed drugs for other companies that would net Pfizer royalties. But cost does matter when assessing a deal and in this case it seems excessive. Pfizer is paying a 62% premium on a stock that had already appreciated by more than 100% in recent months. Acquiring drugs that have been approved is always extra expensive, but Pfizer really ponied up here. Pfizer is paying nearly 8 times Array’s projected 2023 sales, which is higher than what GlaxoSmithKline PLC and Eli Lilly Inc. paid in comparable recent deals for Tesaro Inc. and Loxo Oncology Inc., respectively. Array is expected to generate $274 million in revenue this year, and that figure is expected to pass $1 billion by 2022. That growth is still theoretical, though, and the company’s current product roster would have to exceed expectations to justify this price. Its many partnerships with other companies also limit its upside. All of this suggests that Pfizer is also paying up for Array’s extensive drug development expertise and broader pipeline. It could do worse on that front; Array has been unusually successful at inventing medicines. But Pfizer may not be able to retain the scientists that have turned Array into an R&D powerhouse or get the most out of what’s currently in the company’s labs. Pfizer’s last big oncology deal demonstrates the danger of paying up based on optimistic evaluations. The company bought Medivation for a hefty $14 billion in late 2016 for its prostate-cancer drug Xtandi and several pipeline assets. It’s only been about three years, but so far no part of the deal has lived up to Pfizer’s expectations or the price paid. Array may well help Pfizer transition into a more significant player in the cancer market or prove to be a bargain. But there’s a decent chance that we’ll be back for round three in just a few years. To contact the author of this story: Max Nisen at email@example.comTo contact the editor responsible for this story: Beth Williams at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from GlaxoSmithKline, sending its shares plunging 66%. The study tested VBI's Sci-B-Vac against GSK's Engerix-B, a vaccine which was approved in the United States in 1989. This marks a setback for the vaccine that will likely compete with Heplisav-B, a two-dose vaccine from Dynavax Technologies Corp's which gained FDA approval https://www.reuters.com/article/us-dynavax-techs-fda/dynavaxs-hepatitis-b-vaccine-gets-fda-nod-on-third-try-shares-up-idUSKBN1D93AN in November 2017.
Is GlaxoSmithKline plc (NYSE:GSK) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
GlaxoSmithKline is launching a rare partnership with an American university through which the UK drugmaker will fund more than 20 scientists at a new laboratory focused on human genome research. Under a five-year agreement announced on Thursday, GSK and the university said they will jointly establish the Laboratory for Genomics Research, “to unravel mysteries of the human genome”. The new venture will receive up to $67m in funding from GSK, including facilities for 24 full-time university employees and 14 employees of the pharma group.
Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe. The price tag for the mainly Europe-focused brand portfolio, which include itch relief cream Eurax, antiseptic cream Savlon and Tixylix cough liquids, was in the high double digit million pound range, according to a person close to the deal. Stada declined to comment on the price.
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
U.S. President Donald Trump struck a positive, conciliatory tone with top British and U.S. business leaders at a meeting in London on Tuesday, sources familiar with the talks told Reuters, despite tensions between the two countries over China's Huawei. In a breakfast gathering with 10 executives at St James' Palace, Trump mentioned the strong historical ties between the two countries and praised British investment in the U.S. healthcare sector in particular, the sources said. Trump had earlier promised Britain a substantial post-Brexit trade deal, during a state visit to Britain being cast as a chance to celebrate Britain's "special relationship" with the United States and boost trade links.